Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy - Trial NCT06410300
Access comprehensive clinical trial information for NCT06410300 through Pure Global AI's free database. This phase not specified trial is sponsored by Bo Lu and is currently Recruiting. The study focuses on Lung Cancer. Target enrollment is 125 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bo Lu
University of Missouri-Columbia
Timeline & Enrollment
N/A
Apr 19, 2024
Apr 19, 2030
Primary Outcome
Clinical cardiopulmonary toxicities
Summary
The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with
 lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and
 immunotherapy through timed monitoring and blood sample collection and to identify
 correlative biomarkers for predicting cardiopulmonary adverse events.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06410300
Non-Device Trial